NR565 / NR 565 ADVANCED
PHARMACOLOGY CARE OF THE
FUNDAMENTALS MIDTERM
EXAMPRACTICE QUESTIONS AND
VERIFIED ANSWERS (2023/2024
UPDATE) - CHAMBERLAIN
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS (QUESTIONS 1-25)
QUESTION 1
A patient is prescribed a drug that is a weak base with a pKa of
8.4. In which part of the body will this drug be most highly
ionized?
A) Small intestine (pH 7.4)
B) Stomach (pH 1.5-3.5)
C) Blood (pH 7.35-7.45)
D) Urine (pH 5.0-8.0)
ANSWER: B
RATIONALE: WEAK BASES ARE MORE IONIZED IN
ACIDIC ENVIRONMENTS (LOW PH). THE STOMACH,
WITH ITS HIGHLY ACIDIC PH, WILL CAUSE THE MOST
IONIZATION. IONIZED DRUGS ARE POORLY
ABSORBED ACROSS LIPID MEMBRANES. WEAK ACIDS
,ARE BETTER ABSORBED IN THE STOMACH; WEAK
BASES ARE BETTER ABSORBED IN THE SMALL
INTESTINE.
QUESTION 2
Which pharmacokinetic process is most affected by first-pass
metabolism?
A) Distribution
B) Metabolism
C) Oral absorption
D) Renal excretion
ANSWER: C
RATIONALE: FIRST-PASS METABOLISM OCCURS IN
THE LIVER AND GUT WALL AFTER A DRUG IS
ABSORBED FROM THE GASTROINTESTINAL TRACT
FOLLOWING ORAL ADMINISTRATION. THIS PROCESS
REDUCES THE AMOUNT OF ACTIVE DRUG REACHING
SYSTEMIC CIRCULATION. DRUGS WITH HIGH FIRST-
PASS METABOLISM OFTEN REQUIRE HIGHER ORAL
DOSES OR ALTERNATIVE ROUTES (IV, SUBLINGUAL,
TRANSDERMAL).
QUESTION 3
What does bioavailability refer to?
,A) The amount of drug that reaches systemic circulation
unchanged
B) The rate at which drug is metabolized
C) The time it takes for drug to be eliminated
D) The volume of distribution
ANSWER: A
RATIONALE: BIOAVAILABILITY (F) IS THE FRACTION
OF THE ADMINISTERED DOSE THAT REACHES
SYSTEMIC CIRCULATION UNCHANGED. IV DRUGS
HAVE 100% BIOAVAILABILITY, WHILE ORAL DRUGS
HAVE VARIABLE BIOAVAILABILITY DUE TO
INCOMPLETE ABSORPTION AND FIRST-PASS
METABOLISM.
QUESTION 4
The time required for half of a drug concentration to be
eliminated from the body is called:
A) Peak level
B) Bioavailability
C) Half-life
D) Potency
ANSWER: C
RATIONALE: HALF-LIFE DETERMINES DOSING
INTERVALS AND DURATION OF ACTION. IT IS THE
TIME REQUIRED FOR THE DRUG CONCENTRATION IN
THE BODY TO BE REDUCED BY 50%.
, QUESTION 5
A drug with a narrow therapeutic index (e.g., lithium, warfarin)
requires:
A) Less frequent monitoring
B) More frequent monitoring of serum drug levels
C) Administration with food only
D) Use only in pediatric patients
ANSWER: B
RATIONALE: DRUGS WITH A NARROW THERAPEUTIC
INDEX HAVE A SMALL MARGIN BETWEEN
THERAPEUTIC AND TOXIC DOSES. CLOSE
MONITORING OF SERUM DRUG LEVELS IS ESSENTIAL
TO PREVENT TOXICITY WHILE ENSURING
THERAPEUTIC EFFICACY.
QUESTION 6
The CYP450 enzyme system is primarily responsible for:
A) Drug absorption
B) Drug metabolism
C) Drug distribution
D) Drug excretion
ANSWER: B
RATIONALE: THE CYP450 SYSTEM IS A LIVER ENZYME
SYSTEM WHERE MEDICATIONS ARE METABOLIZED.
PHARMACOLOGY CARE OF THE
FUNDAMENTALS MIDTERM
EXAMPRACTICE QUESTIONS AND
VERIFIED ANSWERS (2023/2024
UPDATE) - CHAMBERLAIN
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS (QUESTIONS 1-25)
QUESTION 1
A patient is prescribed a drug that is a weak base with a pKa of
8.4. In which part of the body will this drug be most highly
ionized?
A) Small intestine (pH 7.4)
B) Stomach (pH 1.5-3.5)
C) Blood (pH 7.35-7.45)
D) Urine (pH 5.0-8.0)
ANSWER: B
RATIONALE: WEAK BASES ARE MORE IONIZED IN
ACIDIC ENVIRONMENTS (LOW PH). THE STOMACH,
WITH ITS HIGHLY ACIDIC PH, WILL CAUSE THE MOST
IONIZATION. IONIZED DRUGS ARE POORLY
ABSORBED ACROSS LIPID MEMBRANES. WEAK ACIDS
,ARE BETTER ABSORBED IN THE STOMACH; WEAK
BASES ARE BETTER ABSORBED IN THE SMALL
INTESTINE.
QUESTION 2
Which pharmacokinetic process is most affected by first-pass
metabolism?
A) Distribution
B) Metabolism
C) Oral absorption
D) Renal excretion
ANSWER: C
RATIONALE: FIRST-PASS METABOLISM OCCURS IN
THE LIVER AND GUT WALL AFTER A DRUG IS
ABSORBED FROM THE GASTROINTESTINAL TRACT
FOLLOWING ORAL ADMINISTRATION. THIS PROCESS
REDUCES THE AMOUNT OF ACTIVE DRUG REACHING
SYSTEMIC CIRCULATION. DRUGS WITH HIGH FIRST-
PASS METABOLISM OFTEN REQUIRE HIGHER ORAL
DOSES OR ALTERNATIVE ROUTES (IV, SUBLINGUAL,
TRANSDERMAL).
QUESTION 3
What does bioavailability refer to?
,A) The amount of drug that reaches systemic circulation
unchanged
B) The rate at which drug is metabolized
C) The time it takes for drug to be eliminated
D) The volume of distribution
ANSWER: A
RATIONALE: BIOAVAILABILITY (F) IS THE FRACTION
OF THE ADMINISTERED DOSE THAT REACHES
SYSTEMIC CIRCULATION UNCHANGED. IV DRUGS
HAVE 100% BIOAVAILABILITY, WHILE ORAL DRUGS
HAVE VARIABLE BIOAVAILABILITY DUE TO
INCOMPLETE ABSORPTION AND FIRST-PASS
METABOLISM.
QUESTION 4
The time required for half of a drug concentration to be
eliminated from the body is called:
A) Peak level
B) Bioavailability
C) Half-life
D) Potency
ANSWER: C
RATIONALE: HALF-LIFE DETERMINES DOSING
INTERVALS AND DURATION OF ACTION. IT IS THE
TIME REQUIRED FOR THE DRUG CONCENTRATION IN
THE BODY TO BE REDUCED BY 50%.
, QUESTION 5
A drug with a narrow therapeutic index (e.g., lithium, warfarin)
requires:
A) Less frequent monitoring
B) More frequent monitoring of serum drug levels
C) Administration with food only
D) Use only in pediatric patients
ANSWER: B
RATIONALE: DRUGS WITH A NARROW THERAPEUTIC
INDEX HAVE A SMALL MARGIN BETWEEN
THERAPEUTIC AND TOXIC DOSES. CLOSE
MONITORING OF SERUM DRUG LEVELS IS ESSENTIAL
TO PREVENT TOXICITY WHILE ENSURING
THERAPEUTIC EFFICACY.
QUESTION 6
The CYP450 enzyme system is primarily responsible for:
A) Drug absorption
B) Drug metabolism
C) Drug distribution
D) Drug excretion
ANSWER: B
RATIONALE: THE CYP450 SYSTEM IS A LIVER ENZYME
SYSTEM WHERE MEDICATIONS ARE METABOLIZED.
